159 related articles for article (PubMed ID: 32410260)
1. The simplified follicular lymphoma PRIMA-prognostic index is useful in patients with first-line chemo-free rituximab-based therapy.
Kimby E; Lockmer S; Holte H; Hagberg H; Wahlin BE; Brown P; Østenstad B
Br J Haematol; 2020 Dec; 191(5):738-747. PubMed ID: 32410260
[TBL] [Abstract][Full Text] [Related]
2. M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy.
Lockmer S; Ren W; Brodtkorb M; Østenstad B; Wahlin BE; Pan-Hammarström Q; Kimby E
Br J Haematol; 2020 Jan; 188(2):259-267. PubMed ID: 31423576
[TBL] [Abstract][Full Text] [Related]
3. Impact of age on clinical risk scores in follicular lymphoma.
Alig S; Jurinovic V; Pastore A; Haebe S; Schmidt C; Zoellner AK; Dreyling M; Unterhalt M; Hoster E; Hiddemann W; Weigert O
Blood Adv; 2019 Apr; 3(7):1033-1038. PubMed ID: 30940638
[TBL] [Abstract][Full Text] [Related]
4. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.
Huet S; Tesson B; Jais JP; Feldman AL; Magnano L; Thomas E; Traverse-Glehen A; Albaud B; Carrère M; Xerri L; Ansell SM; Baseggio L; Reyes C; Tarte K; Boyault S; Haioun C; Link BK; Feugier P; Lopez-Guillermo A; Tilly H; Brice P; Hayette S; Jardin F; Offner F; Sujobert P; Gentien D; Viari A; Campo E; Cerhan JR; Salles G
Lancet Oncol; 2018 Apr; 19(4):549-561. PubMed ID: 29475724
[TBL] [Abstract][Full Text] [Related]
5. Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy.
Mir F; Mattiello F; Grigg A; Herold M; Hiddemann W; Marcus R; Seymour JF; Bolen CR; Knapp A; Nielsen T; Casulo C
Am J Hematol; 2020 Dec; 95(12):1503-1510. PubMed ID: 32815559
[TBL] [Abstract][Full Text] [Related]
6. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.
Pastore A; Jurinovic V; Kridel R; Hoster E; Staiger AM; Szczepanowski M; Pott C; Kopp N; Murakami M; Horn H; Leich E; Moccia AA; Mottok A; Sunkavalli A; Van Hummelen P; Ducar M; Ennishi D; Shulha HP; Hother C; Connors JM; Sehn LH; Dreyling M; Neuberg D; Möller P; Feller AC; Hansmann ML; Stein H; Rosenwald A; Ott G; Klapper W; Unterhalt M; Hiddemann W; Gascoyne RD; Weinstock DM; Weigert O
Lancet Oncol; 2015 Sep; 16(9):1111-1122. PubMed ID: 26256760
[TBL] [Abstract][Full Text] [Related]
7. Long-term survival and prognostic analysis of advanced stage follicular lymphoma in the rituximab era: A China single-center retrospective study.
Zhou Y; Qin Y; He X; Liu P; Yang J; Zhou L; Zhou S; Gui L; Yang S; Zhang C; Shi Y
Asia Pac J Clin Oncol; 2021 Jun; 17(3):289-299. PubMed ID: 32970914
[TBL] [Abstract][Full Text] [Related]
8. Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy.
Murakami S; Kato H; Higuchi Y; Yamamoto K; Yamamoto H; Saito T; Taji H; Yatabe Y; Nakamura S; Kinoshita T
Ann Hematol; 2016 Aug; 95(8):1259-69. PubMed ID: 27220639
[TBL] [Abstract][Full Text] [Related]
9. Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group.
Méndez M; Torrente M; Sánchez-Beato M; González-Rincón J; Royuela A; Gómez-Codina J; de la Cruz-Merino L; Rueda A; Llanos M; Quero C; Rodríguez-Abreu D; Gumá J; Monsalvo S; Sabin P; Provencio M
Hematol Oncol; 2019 Apr; 37(2):143-150. PubMed ID: 30840776
[TBL] [Abstract][Full Text] [Related]
10. Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study†.
Casulo C; Day B; Dawson KL; Zhou X; Flowers CR; Farber CM; Hainsworth JD; Cerhan JR; Link BK; Zelenetz AD; Friedberg JW
Ann Oncol; 2015 Nov; 26(11):2311-7. PubMed ID: 26362568
[TBL] [Abstract][Full Text] [Related]
11. [The clinical features, survival analysis, and geriatric assessment of 85 patients with follicular lymphoma: a single-center study].
Yin JJ; Qian L; Bai JF; Feng R; Li JT; Wang T; Zhang CL; Liu H
Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):233-241. PubMed ID: 38716594
[No Abstract] [Full Text] [Related]
12. Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy.
Maeng CH; Ahn SW; Ryu SY; Han S; Ko YH; Ji JH; Kim WS; Kim SJ
Korean J Intern Med; 2016 May; 31(3):560-9. PubMed ID: 26898595
[TBL] [Abstract][Full Text] [Related]
13. Utility of the Follicular Lymphoma International Prognostic Index and the International Prognostic Index in assessing prognosis and predicting first-line treatment efficacy in follicular lymphoma patients.
Formica V; Norman AR; Cunningham D; Wotherspoon A; Oates J; Chong G
Acta Haematol; 2009; 122(4):193-9. PubMed ID: 19887775
[TBL] [Abstract][Full Text] [Related]
14. Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices.
Nooka AK; Nabhan C; Zhou X; Taylor MD; Byrtek M; Miller TP; Friedberg JW; Zelenetz AD; Link BK; Cerhan JR; Dillon H; Sinha R; Shenoy PJ; Levy D; Dawson K; Hirata JH; Flowers CR
Ann Oncol; 2013 Feb; 24(2):441-448. PubMed ID: 23041589
[TBL] [Abstract][Full Text] [Related]
15. Prognostic ability of five clinical risk scores in follicular lymphoma: A single-center evaluation.
Mozas P; Rivero A; Rivas-Delgado A; Correa JG; Condom M; Nadeu F; Giné E; Delgado J; Villamor N; Campo E; Magnano L; López-Guillermo A
Hematol Oncol; 2021 Dec; 39(5):639-649. PubMed ID: 34494300
[TBL] [Abstract][Full Text] [Related]
16. Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study.
Bachy E; Seymour JF; Feugier P; Offner F; López-Guillermo A; Belada D; Xerri L; Catalano JV; Brice P; Lemonnier F; Martin A; Casasnovas O; Pedersen LM; Dorvaux V; Simpson D; Leppa S; Gabarre J; da Silva MG; Glaisner S; Ysebaert L; Vekhoff A; Intragumtornchai T; Le Gouill S; Lister A; Estell JA; Milone G; Sonet A; Farhi J; Zeuner H; Tilly H; Salles G
J Clin Oncol; 2019 Nov; 37(31):2815-2824. PubMed ID: 31339826
[TBL] [Abstract][Full Text] [Related]
17. A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.
Bachy E; Maurer MJ; Habermann TM; Gelas-Dore B; Maucort-Boulch D; Estell JA; Van den Neste E; Bouabdallah R; Gyan E; Feldman AL; Bargay J; Delmer A; Slager SL; Gomes da Silva M; Fitoussi O; Belada D; Maisonneuve H; Intragumtornchai T; Ansell SM; Lamy T; Dartigues P; Link BK; Seymour JF; Cerhan JR; Salles G
Blood; 2018 Jul; 132(1):49-58. PubMed ID: 29666118
[TBL] [Abstract][Full Text] [Related]
18. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome.
Buske C; Hoster E; Dreyling M; Hasford J; Unterhalt M; Hiddemann W
Blood; 2006 Sep; 108(5):1504-8. PubMed ID: 16690968
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of Treatment in Slovene Follicular Lymphoma Patients.
Južnič Šetina T; Borštnar S; Jezeršek Novaković B
Clin Lymphoma Myeloma Leuk; 2015 Oct; 15(10):586-91. PubMed ID: 26423702
[TBL] [Abstract][Full Text] [Related]
20. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
